Brokers Issue Forecasts for Rocket Pharmaceuticals Inc’s FY2020 Earnings (NASDAQ:RCKT)

Share on StockTwits

Rocket Pharmaceuticals Inc (NASDAQ:RCKT) – Stock analysts at Svb Leerink cut their FY2020 EPS estimates for Rocket Pharmaceuticals in a report released on Thursday, December 5th. Svb Leerink analyst M. Foroohar now anticipates that the biotechnology company will earn ($2.10) per share for the year, down from their previous estimate of ($2.08).

RCKT has been the subject of a number of other research reports. Robert W. Baird lifted their price target on Rocket Pharmaceuticals from $30.00 to $41.00 and gave the stock an “outperform” rating in a research report on Friday. Zacks Investment Research downgraded Rocket Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, October 26th. Piper Jaffray Companies initiated coverage on Rocket Pharmaceuticals in a research note on Thursday, September 26th. They issued an “overweight” rating for the company. Chardan Capital reaffirmed a “buy” rating and set a $30.00 target price on shares of Rocket Pharmaceuticals in a report on Friday. Finally, William Blair reaffirmed a “buy” rating on shares of Rocket Pharmaceuticals in a report on Tuesday, September 10th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Rocket Pharmaceuticals currently has an average rating of “Buy” and an average price target of $31.50.

NASDAQ RCKT opened at $22.37 on Monday. The company has a debt-to-equity ratio of 0.20, a current ratio of 11.07 and a quick ratio of 11.07. The stock’s fifty day moving average price is $15.56 and its 200 day moving average price is $13.98. Rocket Pharmaceuticals has a 1 year low of $10.75 and a 1 year high of $24.42. The company has a market cap of $992.91 million, a price-to-earnings ratio of -11.83 and a beta of 2.78.

Rocket Pharmaceuticals (NASDAQ:RCKT) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.38) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.49) by $0.11.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. boosted its holdings in Rocket Pharmaceuticals by 21.1% in the second quarter. BlackRock Inc. now owns 2,563,600 shares of the biotechnology company’s stock valued at $38,455,000 after purchasing an additional 447,257 shares during the last quarter. Cormorant Asset Management LP lifted its holdings in shares of Rocket Pharmaceuticals by 22.0% in the 2nd quarter. Cormorant Asset Management LP now owns 2,074,595 shares of the biotechnology company’s stock valued at $31,119,000 after buying an additional 374,595 shares during the period. Perceptive Advisors LLC lifted its holdings in shares of Rocket Pharmaceuticals by 331.6% in the 2nd quarter. Perceptive Advisors LLC now owns 1,977,412 shares of the biotechnology company’s stock valued at $29,661,000 after buying an additional 1,519,239 shares during the period. Vanguard Group Inc. boosted its stake in shares of Rocket Pharmaceuticals by 18.6% in the second quarter. Vanguard Group Inc. now owns 1,502,349 shares of the biotechnology company’s stock worth $22,536,000 after buying an additional 235,411 shares during the last quarter. Finally, Eventide Asset Management LLC boosted its stake in shares of Rocket Pharmaceuticals by 42.3% in the third quarter. Eventide Asset Management LLC now owns 1,415,000 shares of the biotechnology company’s stock worth $16,485,000 after buying an additional 420,686 shares during the last quarter. Institutional investors own 93.86% of the company’s stock.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; and leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction It also has additional pre-clinical stage LVV programs include pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption.

Recommended Story: What is total return in investing?

Earnings History and Estimates for Rocket Pharmaceuticals (NASDAQ:RCKT)

Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.